Cvrx, Inc. Stock Price, News & Analysis

CVRx, a commercial-stage medical device company, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's management team is set to present on Wednesday, August 14, 2024, at 12:30 PM Eastern Time. This presentation will be accessible to investors and interested parties through a live audio webcast on the investor relations page of CVRx's official website.

This event provides an opportunity for CVRx to showcase its progress and future plans to a wide audience of investors and industry professionals. The company's participation in such a prominent conference may indicate its commitment to transparency and engagement with the investment community.

CVRx, Inc. (NASDAQ: CVRX) reported strong Q2 2024 financial results, with total revenue reaching $11.8 million, a 24% increase year-over-year. U.S. Heart Failure revenue grew 27% to $10.5 million. The company expanded its active implanting centers in the U.S. by 35% compared to Q2 2023. CVRx appointed new executives, including a Chief Revenue Officer, to strengthen its leadership team. Despite revenue growth, the company reported a net loss of $14.0 million, or $0.65 per share. CVRx updated its full-year 2024 guidance, projecting total revenue between $50.0 million and $53.0 million. The company remains focused on expanding therapy awareness, strengthening clinical evidence, and improving patient access for its Barostim technology.

CVRx, Inc. (NASDAQ: CVRX), a commercial-stage medical device company, has announced its plans to release second quarter 2024 financial and operating results after market close on Monday, July 29th, 2024. The company, which focuses on developing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for cardiovascular diseases, will host a conference call to review its results at 4:30pm Eastern Time on the same day.

Investors and interested parties can access the live webcast of the conference call on the investor relations page of CVRx's website at ir.cvrx.com. For those preferring to listen via telephone, the call-in numbers are 1-877-704-4453 for U.S. callers and 1-201-389-0920 for international callers. It is recommended to dial in approximately ten minutes prior to the start time.

CVRx has appointed Robert John as Chief Revenue Officer, effective June 27. John will lead the US sales team to maximize the impact of Barostim therapy on heart failure patients and establish it as the standard of care in the US. Robert John brings over 25 years of experience in the medical device industry, having previously held significant leadership roles at Abbott and St. Jude Medical. His latest role was Divisional Vice President and General Manager of Cardiac Rhythm Management EMEA at Abbott. John's extensive expertise in building high-performing sales teams and launching heart failure therapies is expected to accelerate CVRx's commercial momentum. John is excited to contribute to CVRx's mission and expand the reach of Barostim therapy.

CVRx, a commercial-stage medical device company, announced that its management team will present at the William Blair 44th Annual Growth Stock Conference on June 5, 2024. The presentation is scheduled for 8:40am Central Time and will be available via live audio webcast on the company's investor relations page.

CVRx, a commercial-stage medical device company, announced the addition of three key executives to its senior leadership team. Dr. Philip B. Adamson will join as Chief Medical Officer, Bonnie Handke as Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics, and Jennifer E. Englund as Senior Vice President of Global Clinical Affairs. These new roles aim to drive the adoption of CVRx's Barostim™ therapy and expand patient access. Dr. Adamson brings nearly three decades of experience in heart failure from Abbott Laboratories, Bonnie Handke comes with extensive experience from Medtronic, and Jennifer Englund has a strong background in leading clinical strategies in the medical device industry. The new hires will focus on making Barostim therapy a standard of care for heart failure patients.

CVRx reported solid financial and operating results for the first quarter of 2024, with total revenue reaching $10.8 million, a 35% increase over the prior year. U.S. Heart Failure revenue grew by 43%, active implanting centers in the U.S. increased by 56%, and gross profit rose by 38%. However, there was a significant increase in SG&A expenses, leading to a net loss of $22.2 million. The company's CEO is addressing commercial execution challenges to scale the business effectively.